Differences

This shows you the differences between two versions of the page.

--- pdl1uppergimarch2026 [2026/04/08 00:45] – gilbert
+++ pdl1uppergimarch2026 [2026/04/08 03:47] (current) – gilbert
@@ Line 7: / Line 7: @@
 Drugs: Pembrolizumab (Merck) and Nivolumab (Bristol Myers Squibb)
-Diagnostic test: PDL1 Dako 22C3 %%PharmDX&&
+Diagnostic test: PDL1 Dako 22C3 %%PharmDX%%
-**Result: CPS < 1 OR CPS >= 1 and < 5 OR CPS >= 5 and < 10 OR CPS >= 10 OR Inadequate**
+**Result: CPS < 1 <color red> **OR** </color> CPS >= 1 and < 5 <color red> **OR** </color> CPS >= 5 and < 10 <color red> **OR** </color> CPS >= 10 <color red> **OR** </color> Inadequate**
 Interpretation: Combined Proportion Score (CPS) - Negative (< 1), other results are interpreted with available biological and clinical parameters.
@@ Line 23: / Line 23: @@
 Test ID: PDL1UPPERGIMARCH2026
+{{:PDL1UPPERGIMARCH2026.docx | PDL1UPPERGIMARCH2026}}
-{{:PDL1UPPERGIMARCH2026.docx | ''PDL1UPPERGIMARCH2026''}}